English (UK)Latvian (LV)Russian (RU)

Injections - Larifans

Prescription medication - use only under doctor's recommendations.

- Treatment of recurrent herpes infections, as well as other infections caused by viruses, including influenza

- Cancer immunotherapy

- Treatment of secondary immunodeficiency of any origin

Shelf life:

3 years

Special storage conditions:

Lariphan solution must be stored in a freezer (temperature no higher than -18 to -200C, minimum temperature is not limited)

Packaging and contents:

In glass bottles containing 2.5 mg/2ml.

Pharmacotherapeutic group:

Antiviral and immunomodulating agent.

Ingredients:

Active substance: double-stranded ribonucleic acid – dsRNS (acidum ribonucleinicum duplicatum). Excipients: NaCl 0, 9% solution.

Activity:

Lariphan is an interferon (IFN) inducer and the resulting biological effects may be caused by both the induced endogenous IFN and the direct activity of the dsRNA molecule. Lariphan is an immunomodulating preparation with antiviral and antitumoral activity.

Therapeutic indications:

- Recurrent herpes virus infection of any localization.

- Secondary immunodeficiency of any origin (caused by viral infections or anti-cancer medicaments etc.)

Dosage and application:

Lariphan is injected subcutaneously. In case of a recurrent herpes virus infection the dose is 2.5 mg once a day, five times (1st, 2nd, 6th, 10th and 14th day). Courses are repeated 5 times at 4 week intervals. For immunodeficiency treatment: dose rate 2.5 mg once a day, four times at weekly intervals, courses have to be repeated after a break of 1 or 2 months.

Contacts

Larifans Ltd

Kurbada street 2b, Riga, LV-1009

Phone/ Fax: +371 67427462

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Other information

- Scientific publications

- ERDF

Eraf